Cargando…

Toosendanin, a novel potent vacuolar-type H(+)-translocating ATPase inhibitor, sensitizes cancer cells to chemotherapy by blocking protective autophagy

Macroautophagy/autophagy is the process of self-digestion through the lysosomes; it disassembles unnecessary or dysfunctional long-lived proteins and damaged organelles for the recycling of biomacromolecules. Unfortunately, cancer cells can hijack this mechanism to survive under metabolic stress or...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Yu, Zhu, Guoyuan, Wang, Sheng-Fang, Keon, Kristine A., Rubinstein, John L., Zeng, Si-Xin, Zhang, Shuang, Chen, Qiu-Ling, Fu, Jing, Li, Min, Shen, Han-Ming, Lu, Jin-Jian, Chen, Xiu-Ping, Lu, Jia-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066121/
https://www.ncbi.nlm.nih.gov/pubmed/35541921
http://dx.doi.org/10.7150/ijbs.71041
_version_ 1784699737757188096
author Dong, Yu
Zhu, Guoyuan
Wang, Sheng-Fang
Keon, Kristine A.
Rubinstein, John L.
Zeng, Si-Xin
Zhang, Shuang
Chen, Qiu-Ling
Fu, Jing
Li, Min
Shen, Han-Ming
Lu, Jin-Jian
Chen, Xiu-Ping
Lu, Jia-Hong
author_facet Dong, Yu
Zhu, Guoyuan
Wang, Sheng-Fang
Keon, Kristine A.
Rubinstein, John L.
Zeng, Si-Xin
Zhang, Shuang
Chen, Qiu-Ling
Fu, Jing
Li, Min
Shen, Han-Ming
Lu, Jin-Jian
Chen, Xiu-Ping
Lu, Jia-Hong
author_sort Dong, Yu
collection PubMed
description Macroautophagy/autophagy is the process of self-digestion through the lysosomes; it disassembles unnecessary or dysfunctional long-lived proteins and damaged organelles for the recycling of biomacromolecules. Unfortunately, cancer cells can hijack this mechanism to survive under metabolic stress or develop drug resistance during chemotherapy. Increasing evidence indicates that the combination of autophagy inhibition and chemotherapy is a promising cancer treatment strategy. However, effective autophagy inhibitors with satisfied potency, bioavailability, and clearly-defined drug targets are still rare. Here, we report the identification of a potent autophagy inhibitor toosendanin which can effectively block autophagosome maturation, causing the accumulation of autophagy substrates in multiple cancer cells. Toosendanin did not inhibit the fusion process between autophagosome and lysosome but elevated lysosomal pH and impaired lysosomal enzymes activity. Using rat liver lysosome fraction and purified yeast V-ATPase, we found that toosendanin directly inhibited V-ATPase activity. By applying cellular thermal shift assay (CETSA), immunoprecipitation-coupled LC-MS/MS analysis, and biotin-toosendanin pull-down assay, we confirmed the direct binding between toosendanin and V-ATPase. Furthermore, toosendanin blocked chemotherapy-induced protective autophagy in cultured cancer cells and xenograft tumor tissues to significantly enhance anti-cancer activity. These results suggest that toosendanin has the potential to be developed into an anti-cancer drug by blocking chemotherapy-induced protective autophagy.
format Online
Article
Text
id pubmed-9066121
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-90661212022-05-09 Toosendanin, a novel potent vacuolar-type H(+)-translocating ATPase inhibitor, sensitizes cancer cells to chemotherapy by blocking protective autophagy Dong, Yu Zhu, Guoyuan Wang, Sheng-Fang Keon, Kristine A. Rubinstein, John L. Zeng, Si-Xin Zhang, Shuang Chen, Qiu-Ling Fu, Jing Li, Min Shen, Han-Ming Lu, Jin-Jian Chen, Xiu-Ping Lu, Jia-Hong Int J Biol Sci Research Paper Macroautophagy/autophagy is the process of self-digestion through the lysosomes; it disassembles unnecessary or dysfunctional long-lived proteins and damaged organelles for the recycling of biomacromolecules. Unfortunately, cancer cells can hijack this mechanism to survive under metabolic stress or develop drug resistance during chemotherapy. Increasing evidence indicates that the combination of autophagy inhibition and chemotherapy is a promising cancer treatment strategy. However, effective autophagy inhibitors with satisfied potency, bioavailability, and clearly-defined drug targets are still rare. Here, we report the identification of a potent autophagy inhibitor toosendanin which can effectively block autophagosome maturation, causing the accumulation of autophagy substrates in multiple cancer cells. Toosendanin did not inhibit the fusion process between autophagosome and lysosome but elevated lysosomal pH and impaired lysosomal enzymes activity. Using rat liver lysosome fraction and purified yeast V-ATPase, we found that toosendanin directly inhibited V-ATPase activity. By applying cellular thermal shift assay (CETSA), immunoprecipitation-coupled LC-MS/MS analysis, and biotin-toosendanin pull-down assay, we confirmed the direct binding between toosendanin and V-ATPase. Furthermore, toosendanin blocked chemotherapy-induced protective autophagy in cultured cancer cells and xenograft tumor tissues to significantly enhance anti-cancer activity. These results suggest that toosendanin has the potential to be developed into an anti-cancer drug by blocking chemotherapy-induced protective autophagy. Ivyspring International Publisher 2022-03-28 /pmc/articles/PMC9066121/ /pubmed/35541921 http://dx.doi.org/10.7150/ijbs.71041 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Dong, Yu
Zhu, Guoyuan
Wang, Sheng-Fang
Keon, Kristine A.
Rubinstein, John L.
Zeng, Si-Xin
Zhang, Shuang
Chen, Qiu-Ling
Fu, Jing
Li, Min
Shen, Han-Ming
Lu, Jin-Jian
Chen, Xiu-Ping
Lu, Jia-Hong
Toosendanin, a novel potent vacuolar-type H(+)-translocating ATPase inhibitor, sensitizes cancer cells to chemotherapy by blocking protective autophagy
title Toosendanin, a novel potent vacuolar-type H(+)-translocating ATPase inhibitor, sensitizes cancer cells to chemotherapy by blocking protective autophagy
title_full Toosendanin, a novel potent vacuolar-type H(+)-translocating ATPase inhibitor, sensitizes cancer cells to chemotherapy by blocking protective autophagy
title_fullStr Toosendanin, a novel potent vacuolar-type H(+)-translocating ATPase inhibitor, sensitizes cancer cells to chemotherapy by blocking protective autophagy
title_full_unstemmed Toosendanin, a novel potent vacuolar-type H(+)-translocating ATPase inhibitor, sensitizes cancer cells to chemotherapy by blocking protective autophagy
title_short Toosendanin, a novel potent vacuolar-type H(+)-translocating ATPase inhibitor, sensitizes cancer cells to chemotherapy by blocking protective autophagy
title_sort toosendanin, a novel potent vacuolar-type h(+)-translocating atpase inhibitor, sensitizes cancer cells to chemotherapy by blocking protective autophagy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066121/
https://www.ncbi.nlm.nih.gov/pubmed/35541921
http://dx.doi.org/10.7150/ijbs.71041
work_keys_str_mv AT dongyu toosendaninanovelpotentvacuolartypehtranslocatingatpaseinhibitorsensitizescancercellstochemotherapybyblockingprotectiveautophagy
AT zhuguoyuan toosendaninanovelpotentvacuolartypehtranslocatingatpaseinhibitorsensitizescancercellstochemotherapybyblockingprotectiveautophagy
AT wangshengfang toosendaninanovelpotentvacuolartypehtranslocatingatpaseinhibitorsensitizescancercellstochemotherapybyblockingprotectiveautophagy
AT keonkristinea toosendaninanovelpotentvacuolartypehtranslocatingatpaseinhibitorsensitizescancercellstochemotherapybyblockingprotectiveautophagy
AT rubinsteinjohnl toosendaninanovelpotentvacuolartypehtranslocatingatpaseinhibitorsensitizescancercellstochemotherapybyblockingprotectiveautophagy
AT zengsixin toosendaninanovelpotentvacuolartypehtranslocatingatpaseinhibitorsensitizescancercellstochemotherapybyblockingprotectiveautophagy
AT zhangshuang toosendaninanovelpotentvacuolartypehtranslocatingatpaseinhibitorsensitizescancercellstochemotherapybyblockingprotectiveautophagy
AT chenqiuling toosendaninanovelpotentvacuolartypehtranslocatingatpaseinhibitorsensitizescancercellstochemotherapybyblockingprotectiveautophagy
AT fujing toosendaninanovelpotentvacuolartypehtranslocatingatpaseinhibitorsensitizescancercellstochemotherapybyblockingprotectiveautophagy
AT limin toosendaninanovelpotentvacuolartypehtranslocatingatpaseinhibitorsensitizescancercellstochemotherapybyblockingprotectiveautophagy
AT shenhanming toosendaninanovelpotentvacuolartypehtranslocatingatpaseinhibitorsensitizescancercellstochemotherapybyblockingprotectiveautophagy
AT lujinjian toosendaninanovelpotentvacuolartypehtranslocatingatpaseinhibitorsensitizescancercellstochemotherapybyblockingprotectiveautophagy
AT chenxiuping toosendaninanovelpotentvacuolartypehtranslocatingatpaseinhibitorsensitizescancercellstochemotherapybyblockingprotectiveautophagy
AT lujiahong toosendaninanovelpotentvacuolartypehtranslocatingatpaseinhibitorsensitizescancercellstochemotherapybyblockingprotectiveautophagy